IL-6 family cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets

Abstract IL-6 is a critical cytokine in acute phase responseand involved in the pathogenesis of several chronic inflammatory diseases including cancer. Studies have highlighted that levels of IL-6 and its family members can be useful for diagnosis, prognosis of relapse-free survival and recurrence. IL-6 family cytokines have been identified as cancer biomarkersthrough screening of inflammatory mediators in different fluids including saliva, serum, and bronchoalveolar lavagefluid (BALF). IL-6 can be modulated by chemopreventive drugs, small molecules, monoclonal antibodies and immune checkpointinhibitors. Unveiling the different sources of IL-6, the interaction between IL-6 and its cellular targets, the IL-6-dependent tumor resistance mechanisms, and the identification of novel regulators of IL-6 are some of the highly complex topics included in this review and their understanding could aid cancer biomarkersand therapy development.